Davunetide
| Code | Size | Price |
|---|
| TAR-T21470-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T21470-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Davunetide is an eight amino acid peptide (NAPVSIPQ) with potent neuroprotection in vitro and in vivo. Davunetide has been shown to enhance functional daily behaviors in schizophrenia patients and to increase memory scores in patients suffering from amnestic mild cognitive impairment.
CAS:
211439-12-2
Formula:
C36H60N10O12
Molecular Weight:
824.934
Purity:
0.98
SMILES:
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O
References
1. Arya A, Meena R, Sethy NK, Das M, Sharma M, Bhargava K. NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions. Free Radic Res. 2015 Apr;49(4):440-52. doi: 10.3109/10715762.2015.1011153. Epub 2015 Mar 2. PubMed PMID: 25727410.
2. Magen I, Ostritsky R, Richter F, Zhu C, Fleming SM, Lemesre V, Stewart AJ, Morimoto BH, Gozes I, Chesselet MF. Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing ?-synuclein. Pharmacol Res Perspect. 2014 Oct;2(5):e00065. doi: 10.1002/prp2.65. Epub 2014 Aug 6. PubMed PMID: 25505609; PubMed Central PMCID: PMC4186425.
3. Sethy NK, Sharma NK, Das M, Bhargava K. Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia. J Mol Neurosci. 2014 Nov;54(3):414-29. doi: 10.1007/s12031-014-0381-9. Epub 2014 Jul 20. PubMed PMID: 25038875.
4. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, H?glinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27. PubMed PMID: 24873720; PubMed Central PMCID: PMC4129545.